– Quantitative three-pronged program to improve bone and total body health –
ASHBURN, Va., Sept. 16, 2022 /PRNewswire/ — Osteoporosis is a complex and multifactorial disorder that is growing in prevalence. More than half of Medicare-aged women and more than a fifth of comparable age men have one or more osteoporotic fractures confirmed during their lifetime. Recovery from large bone fractures is slow and leads to a more sedentary and less engaged life with greater morbidity and accelerated mortality.
“Natural Bone Health: A Practitioner’s Guide to Healthy Bone, Joints and Muscles” is now available for purchase.
Thought-leading scientist and integrative healthcare pioneer, Russell Jaffe, MD, PhD, and natural bone health expert Susan Brown, PhD, CNS, with contributors Jayashree Mani, MS, CCN and Marcy Jaffe, MPA, MBA, explore the components of bone health – from submolecular to macromolecular – and offer a quantitative approach to epigenetic factors, providing simple clinically-useful integrative tests and a targeted action plan that includes diet, hydration, supplementation and lifestyle recommendations that will protect bone, joint and muscle health as we age.
The book covers an “Alkaline Way” approach to bone and body health consisting of:
Measuring and Correcting Net Acid Excess
Measuring and Reducing Inflammation and Oxidative Stress
Evaluating Neurohormone Status
Dr. Brown notes, “While the average woman loses roughly 45% of her bone density between the ages of 35 and 85, we see clients stabilize bone mass quickly, with bone mass gains over the longer term being more the rule than the exception. Those who diligently work through the steps of our program put control back into their control systems, gain bone strength, and reduce fracture risk.”
Natural Bone Health: A Practitioner’s Guide to Healthy Bone, Joints and Muscles is now available for purchase on Amazon.com and at https://www.perqueintegrativehealth.com/natural-bone-health-a-practitioners-guide-to-healthy-bone-joints-and-muscles/
About the Authors
Russell Jaffe, MD, Ph.D., CCN, is an internist and immunologist. He is board-certified in clinical pathology, with subspecialty board certification in chemical pathology. Russ is a Fellow of the following medical societies: ASCP, ACAAI, ACN, ASIP, and FRSM. Dr. Jaffe helped advance several adjunctive healthcare approaches including medical acupuncture (TCM), certified clinical nutrition (CCN), health coaching, and predictive biomarkers. Enabling primary, proactive prevention in clinical practice is part of Dr. Jaffe’s mission to speed the transition from sick care to healthful caring in policy, practice and research. With over 100 peer reviewed publications, invited chapters, and books, Dr. Jaffe speaks at continuing professional education conferences and in technology innovation forums. Dr. Jaffe is director of ELISA/ACT Biotechnologies (Sterling, VA), PERQUE (Ashburn, VA), RMJ Holdings (Vienna, VA) and serves as a founding Fellow of the Health Studies Collegium. He works and lives in Virginia.
Susan E. Brown, Ph.D., CNS, is a medical anthropologist and certified clinical nutritionist (CCN). She directs the Better Bones Foundation and Center for Better Bones in East Syracuse, NY. Dr. Brown conducts primary research, and lectures widely on osteoporosis, teaching her natural Better Bones, Better Body Program for the regeneration of bone health. Dr. Brown’s publications include The Acid Alkaline Food Guide (Square One Publishers 2006, 2013) Better Bones, Better Body: Beyond Estrogen and Calcium: A Comprehensive Self-Help Program for Preventing, Halting & Overcoming Osteoporosis (New Canaan: Keats, 1996, 2000); The Mend Clinic Book of Natural Remedies for Menopause and Beyond (Dell, 1997), co-authored with Dr. Paula Maas. Information on Dr. Brown’s works can be found at www.betterbones.com. Susan works and lives in East Syracuse, New York.
Jayashree Mani MS, CCN is a Certified Clinical Nutritionist  and has focused on diabetes, weight management, integrative nutrition and lifestyle management. She has been providing nutritional counseling and education to patients in various medical settings for more than 20 years. With her expertise in the field of autoimmunity, she has also co-authored chapters and articles in key reference books and scientific journals and is a Certified Nutrition Specialist supervisor. Jayashree is also involved in product formulation and actively educating practitioners and helping patients achieve lifetime wellness. Jayashree works and lives in northern Virginia.
Marcy Jaffe, MPA, MBA, serves as a health advocate with Thinking of  You since 1997: http://www.vitamins-today.com. She successfully achieves improved bone health outcomes one client at a time, through increasing magnesium reserves and recommending the Alkaline Way Lifestyle. Marcy successfully completed the PIH Academy Course 1 Certification in 2019. Marcy works and lives in small towns of western Washington and southern Arizona.
View original content to download multimedia:https://www.prnewswire.com/news-releases/wellness-pioneer-russell-jaffe-md-phd-ccn-and-bone-health-expert-susan-brown-phd-cns-launch-book-natural-bone-health-a-practitioners-guide-to-healthy-bone-joints-and-muscles-301625822.html
SOURCE PERQUE Integrative Health
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
In a recent interview with PEOPLE, the couple, whose real-life love story was portrayed in The Big Sick, opened up about what it's like to be in the immunocompromised community
Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
The latest clinical news from Bristol Myers Squibb (NYSE: BMY) was quite encouraging, sufficient to drive the pharmaceutical giant's stock higher on an otherwise uninspired day for the broader stock market. Bristol Myers Squibb's share price experienced a nearly 2% bump, a notably better showing than the S&P 500 index's more than 1% decline. Bristol Myers Squibb's good news from the lab was that its enduringly popular cancer drug Opdivo did quite well in its latest round of testing.
Updated COVID-19 boosters targeting specific omicron strains of the coronavirus are now available. Here are the most common side effects you might experience.
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
"If we are forcing millions of people into this world, we as a society — whether you are right, whether you are left, whether you are 'pro-life' or not — it doesn't matter. You will all suffer the consequences of a crowded, broken political, healthcare, and education system."View Entire Post ›
Pharmaceutical giant Merck (NYSE: MRK) delivered outstanding second-quarter results in July, largely driven by its mainstay cancer blockbuster, Keytruda. The company reported 28% year-over-year total revenue growth and continues to develop Keytruda for new cancer indications. Under the radar, however, Keytruda returned some bad news in three separate late-stage clinical trials this summer.
In June, a Dallas area doctor who was feeling unwell wanted to use a saline IV bag she had gotten from her work to try to rehydrate. She tapped it into her veins while at home. Minutes later, she suffered a major medical event and died, court records say. Now, Raynaldo Rivera Ortiz Jr., an anesthesiologist at her surgical facility, faces federal charges for allegedly tampering with IV bags in a way that resulted in the death of his colleague as well as several other cardiac emergencies, accordin
The San Carlos company has 125 employees and is applying its pulsed electric field systems in lung cancer and, potentially, drug delivery.

source